Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03195400 · ClinicalTrials.gov registry record
Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes
A clinical trial of T2D and IGT - Impaired Glucose Tolerance, sponsored by Yale University.
- Completed
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT03195400: Completed study of T2D and IGT - Impaired Glucose Tolerance, sponsored by Yale University.
NCT03195400 is a study of T2D and IGT - Impaired Glucose Tolerance that has completed, run by Yale University. The registered enrollment target is 100 participants, below the 324-participant average among 3 other T2D trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03195400, a study of T2D and IGT - Impaired Glucose Tolerance, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Type 2 Diabetes (T2D) in obese youth is often preceded by a prediabetic state called: Impaired Glucose Tolerance (IGT), which is associated with a pre-existing defect in insulin secretion. This study intends to determine if genetic factors are associated with defects in insulin secretion, the incretin system and hepatic insulin resistance in obese adolescents. The long-term goal of this study is to generate information on both the genetics as well as the pathophysiology of Type 2 Diabetes in Youth, which ultimately might guide the investigators towards better preventive and treatment avenues.
Primary Outcome
An oral glucose tolerance test will be performed to assess glucose tolerance status to determine if subjects are pre-IGT or IGT
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Oral Glucose Tolerance Test
- DIAGNOSTIC_TEST Hyperglycemic Clamp
- DIAGNOSTIC_TEST Isoglycemic Intravenous Glucose Test
- DIAGNOSTIC_TEST Hyperinsulinemic Euglycemic Clamp and 2H20
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2022-08-12 |
What the finished NCT03195400 record still lists
NCT03195400 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 324-participant average among 3 other T2D trials with a reported enrollment target (69% lower).
The record links to 2 conditions, with T2D appearing as the primary indexed condition, and to 4 interventions - of which Oral Glucose Tolerance Test is the first listed.
NCT03195400 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03195400 about?
NCT03195400 is a clinical study titled "Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes". Type 2 Diabetes (T2D) in obese youth is often preceded by a prediabetic state called: Impaired Glucose Tolerance (IGT), which is associated with a pre-existing defect in insulin secretion. This study intends to determine if genetic factors are associated with defects in insulin secretion, the incret...
What is the current status of trial NCT03195400?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2017-03-01. Estimated completion is 2022-08-12.
What conditions does trial NCT03195400 study?
This clinical trial studies the following conditions: T2D, IGT - Impaired Glucose Tolerance.
What interventions are being tested in trial NCT03195400?
The interventions under investigation include: Oral Glucose Tolerance Test (DIAGNOSTIC_TEST), Hyperglycemic Clamp (DIAGNOSTIC_TEST), Isoglycemic Intravenous Glucose Test (DIAGNOSTIC_TEST), Hyperinsulinemic Euglycemic Clamp and 2H20 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03195400?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03195400 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T2D
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D
RECRUITING
-
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI